Does BHMT rs3733890 reduce the flexibility of the betaine-dependent backup pathway for converting homocysteine to methionine?

The betaine-homocysteine S-methyltransferase (BHMT) pathway serves as a vital, folate-independent backup system that remethylates homocysteine into methionine using betaine as a methyl donor. Genetic variations in this pathway can significantly alter how the body maintains homocysteine homeostasis and responds to nutritional therapies.

Mechanistic impact on one-carbon metabolism

• Enzyme alteration: The BHMT rs3733890 (742G>A, R239Q) polymorphism is a non-synonymous coding variant that alters the enzyme's amino acid sequence and biochemical affinity for homocysteine.
• Loss of metabolic flexibility: This variation modulates the betaine-dependent conversion of homocysteine to methionine, compromising the flexibility of this alternative pathway and shifting metabolic dependence toward alternative nutrient pools.

Clinical and therapeutic implications

• Folate therapy resistance: Individuals carrying the rs3733890 variant, particularly those with the homozygous mutant (AA) genotype, demonstrate a significantly reduced capacity to lower elevated homocysteine using folate-only therapy. This genetic profile increases the risk of folate treatment failure, placing a higher metabolic demand on dietary choline and betaine supplies to achieve homocysteine clearance.
• Developmental susceptibility: In specific clinical cohorts, the rs3733890 A allele acts as a genetic susceptibility modifier, significantly increasing the risk of neural tube defects due to altered methylation capacity during critical developmental windows.

Bottom line

• The BHMT rs3733890 variant reduces the functional flexibility of the betaine-dependent backup pathway, making homocysteine regulation highly sensitive to choline and betaine status and reducing the clinical efficacy of standard folate-only interventions.